Insmed chief people strategy officer sells $1.9 million in stock

BRIDGEWATER, N.J.—S. Nicole Schaeffer, the Chief People Strategy Officer at Insmed Inc (NASDAQ:INSM), recently executed a significant stock transaction. The company, currently valued at $14.3 billion, has seen its stock surge nearly 180% over the past year, according to InvestingPro data. On February 6, Schaeffer sold 23,500 shares of Insmed common stock, generating approximately $1.9 million. The shares were sold at a weighted average price of $80.90, with individual sale prices ranging from $80.57 to $81.43. The transaction occurs as the stock trades near its 52-week high of $82.04, with analysts maintaining a strong buy consensus and a high price target of $105.

The sale was conducted to satisfy tax withholding obligations and cover related broker fees following the vesting of Performance Stock Units (PSUs). These PSUs, originally granted on January 6, 2022, vested on February 5, 2025, upon meeting specific performance and service conditions.

Following the transaction, Schaeffer retains direct ownership of 120,878 shares of Insmed.

In other recent news, Insmed Incorporated received a priority review from the U.S. Food and Drug Administration for its brensocatib, a potential treatment for non-cystic fibrosis bronchiectasis. The application was supported by data from the Phase 3 ASPEN study, which achieved its primary endpoint. Insmed also plans to submit regulatory filings for brensocatib in the European Union, the United Kingdom (TADAWUL:4280), and Japan within 2025.

In analyst-related news, Truist Securities maintained a Buy rating on Insmed with a steady $105 price target. The firm highlighted several upcoming catalysts for Insmed, including the potential multi-billion dollar market for brensocatib in bronchiectasis and the expected release of Phase 2 top-line data for the treatment of pulmonary arterial hypertension (PAH) with TPIP in mid-2025. Mizuho (NYSE:MFG) Securities also adjusted its price target for Insmed to $88, maintaining an Outperform rating despite the reduction.

Other recent developments include Insmed’s termination of a significant sales agreement with Leerink Partners LLC, effectively immediately. The agreement, established in 2024, allowed Insmed to sell up to $500 million of its common stock through Leerink. Lastly, Insmed reported preliminary sales of its drug Arikayce for fiscal year 2024, surpassing both the company’s own guidance and consensus estimates. The company projects global revenues for Arikayce in fiscal year 2025 to reach between $405 million and $425 million. These are among the recent developments that have shaped Insmed’s trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.